Congratulations on a new FDA Approval - Contrave

PMG is excited to share that Takeda Pharmaceuticals and Orexigen® Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or those who are overweight with at least one weight-related comorbid condition (such as hypertension, hyperlipidemia, or diabetes).

All ten PMG Research sites, and nearly 1,000 patient volunteers participated in the various studies leading up to the approval of Contrave. We would like to extend a special thank you to our volunteers, physician investigators, and site staff who all contributed to this success. It is always so exciting to see clinical research lead to FDA approval and the potential to help so many people.

To learn more: 

• Visit the FDA website
• Read the press release from Takeda and Orexigen
• To learn more about Contrave and its indications, please speak with your doctor.

To learn more about currently enrolling studies at PMG Research, visit our website at www.PMG-Research.com.